Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 single-dose safety and bronchodilation study in allergic asthma
NL-OMON34422Phase 2Active, not recruiting
- Sponsor
- Verona Pharma
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in asthma and allergic asthma (3 arms), sponsored by Verona Pharma. Primary endpoints: Respiratory safety, Gastrointestinal safety and tolerability and 5 more. Started Nov 2010; status: active, not recruiting.
02
Drugs
ensifentrine
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on NL-OMON34422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34422.